Effect of nonalcoholic fatty liver disease on the development of type 2 diabetes in nonobese, nondiabetic Korean men

Gut and Liver

Volumn 6, Issue 3, 2012, Pages 368-373

  Chon, Chang Wook ^a   Kim, Bum Soo ^a   Cho, Yong Kyun ^a   Sung, Ki Chul ^a   Bae, Ji Cheol ^b   Kim, Tae Wan ^a   Won, Hyun Sun ^a   Joo, Kwan Joong ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Samsung Medical Center   (South Korea)

Author keywords

Metabolic syndrome; Nonalcoholic fatty liver disease; Type 2 diabetes mellitus

Indexed keywords

GLUCOSE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HOMEOSTATIC MODEL ASSESSMENT INSULIN RESISTANCE; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALE; MEDICAL EXAMINATION; MEDICAL PARAMETERS; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; RISK; RISK ASSESSMENT; RISK FACTOR; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84865425672     PISSN: 19762283     EISSN: None     Source Type: Journal    
DOI: 10.5009/gnl.2012.6.3.368     Document Type: Article

References (31)

1. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 2001;21:3-16. (Pubitemid 32240482)
2. Park SH, Jeon WK, Kim SH, et al. Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults. J Gastroenterol Hepatol 2006;21(1 Pt 1):138-143.
3. Farrell GC. Non-alcoholic steatohepatitis: what is it, and why is it important in the Asia-Pacific region? J Gastroenterol Hepatol 2003;18:124-138. (Pubitemid 36349857)
4. Choudhury J, Sanyal AJ. Clinical aspects of fatty liver disease. Semin Liver Dis 2004;24:349-362. (Pubitemid 40052626)
5. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415-1428. (Pubitemid 40523737)
6. Fan JG, Zhu J, Li XJ, et al. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J Hepatol 2005;43:508-514. (Pubitemid 41111434)
7. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917-923. (Pubitemid 36397405)
8. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001;50:1844-1850. (Pubitemid 33641605)
9. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005;42:44-52. (Pubitemid 40911310)
10. Knobler H, Schattner A, Zhornicki T, et al. Fatty liver: an additional and treatable feature of the insulin resistance syndrome. QJM 1999;92:73-79. (Pubitemid 29097631)
11. Seppälä-Lindroos A, Vehkavaara S, Häkkinen AM, et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 2002;87:3023-3028.
12. Day CP, Saksena S. Non-alcoholic steatohepatitis: definitions and pathogenesis. J Gastroenterol Hepatol 2002;17 Suppl 3:S377-S384. (Pubitemid 35454314)
13. Exert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
14. American Diabetes Association. Standards of medical care in diabetes: 2010. Diabetes Care 2010;33 Suppl 1:S11-S61.
15. Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002;123:745-750. (Pubitemid 34977081)
16. Fan JG, Zhu J, Li XJ, et al. Fatty liver and the metabolic syndrome among Shanghai adults. J Gastroenterol Hepatol 2005;20:1825-1832. (Pubitemid 43961036)
17. Friis-Liby I, Aldenborg F, Jerlstad P, Rundström K, Björnsson E. High prevalence of metabolic complications in patients with non-alcoholic fatty liver disease. Scand J Gastroenterol 2004;39:864-869. (Pubitemid 39215458)
18. Fan JG, Fang JW, Lu YS, Qian Y, Cai XB. A study of the changes of hepatic gene expression in the process of nonalcoholic fatty liver disease development using U230A oligonucleotide microarray. Zhonghua Gan Zang Bing Za Zhi 2005;13:597-601.
19. Ekstedt M, Franzén LE, Mathiesen UL, Holmqvist M, Bodemar G, Kechagias S. Survival and causes of death in patients with elevated liver enzymes associated with non-alcoholic fatty liver disease (NAFLD). J Hepatol 2006;44 Suppl 2:S40-S41.
20. Singh SP. Non-alcoholic fatty liver disease: the unfolding monster? J Gastroenterol Hepatol 2006;21(1 Pt 2):199-201.
21. Hamaguchi M, Kojima T, Takeda N, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005;143:722-728.
22. Paradis V, Perlemuter G, Bonvoust F, et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 2001;34:738-744. (Pubitemid 32927998)
23. Ozcan U, Cao Q, Yilmaz E, et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004;306:457-461. (Pubitemid 39372439)
24. Svegliati-Baroni G, Ridolfi F, Di Sario A, et al. Insulin and insulin-like growth factor-1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways. Hepatology 1999;29:1743-1751. (Pubitemid 29247048)
25. Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001;120:1183-1192. (Pubitemid 32246672)
26. Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999;107:450-455. (Pubitemid 29528333)
27. Bae JC, Cho YK, Lee WY, et al. Impact of nonalcoholic fatty liver disease on insulin resistance in relation to HbA1c levels in nondiabetic subjects. Am J Gastroenterol 2010;105:2389-2395.
28. Stefan N, Kantartzis K, Häring HU. Causes and metabolic consequences of fatty liver. Endocr Rev 2008;29:939-960.
29. Fan JG, Li F, Cai XB, Peng YD, Ao QH, Gao Y. Effects of nonalcoholic fatty liver disease on the development of metabolic disorders. J Gastroenterol Hepatol 2007;22:1086-1091. (Pubitemid 47019857)
30. Shibata M, Kihara Y, Taguchi M, Tashiro M, Otsuki M. Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men. Diabetes Care 2007;30:2940-2944. (Pubitemid 350083148)
31. Kim HJ, Lee KE, Kim DJ, et al. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Arch Intern Med 2004;164:2169-2175.